Literature DB >> 17448534

The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries.

Eisuke Shiozawa1, Toshiko Yamochi-Onizuka, Masafumi Takimoto, Hidekazu Ota.   

Abstract

Patients with the germinal center B-cell-like (GCB) subtype of diffuse large B-cell lymphoma (DLBCL) have a significantly better survival rate than those with non-GCB DLBCL. Several studies have examined the proportions of GCB and non-GCB subtypes in large series of DLBCL patients, but it remains unclear if these proportions are the same in different countries. We performed an immunohistochemical analysis of the numbers of GCB and non-GCB subtypes in a large number of patients with DLBCL in Japan and compared the results with literature data for other countries. We found that 71 of 248 patients (29%) had the GCB phenotype and 177 patients (71%) had the non-GCB subtype of DLBCL among our patient population. Assessment of data collected from other studies showed that 31% of DLBCL patients (102/330) have the GCB subtype in Asian countries, but 50% (206/416) express GCB phenotypes in Western countries; based on these data, the occurrence of the GCB subtype of DLBCL was significantly less in Asian countries (p<0.001). Since patients with the GCB phenotype of DLBCL have better survival, future studies of DLBCL should recognize the difference in the proportions of GCB and non-GCB subtypes of DLBCL between Asian and Western populations.

Entities:  

Mesh:

Year:  2007        PMID: 17448534     DOI: 10.1016/j.leukres.2007.03.017

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  20 in total

1.  Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.

Authors:  Sukjoong Oh; Dong Hoe Koo; Cheolwon Suh; Shin Kim; Bong Hee Park; Joon Kang; Jooryung Huh
Journal:  J Korean Med Sci       Date:  2011-11-29       Impact factor: 2.153

2.  New Challenges in the Management of Diffuse Large B-Cell Lymphoma.

Authors:  Christopher R Flowers; Loretta J Nastoupil; Leon Bernal-Mizrachi; Adam C Rose; Rajni Sinha
Journal:  Treat Strategies Hematol       Date:  2012-01

3.  Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma.

Authors:  Grzegorz S Nowakowski; Annalisa Chiappella; Thomas E Witzig; David W Scott; Michele Spina; Randy D Gascoyne; Lei Zhang; Jacqueline Russo; Janet Kang; Jingshan Zhang; Yingyong Xu; Umberto Vitolo
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

4.  Examining racial differences in diffuse large B-cell lymphoma presentation and survival.

Authors:  Christopher R Flowers; Pareen J Shenoy; Uma Borate; Kevin Bumpers; Tanyanika Douglas-Holland; Nassoma King; Otis W Brawley; Joseph Lipscomb; Mary Jo Lechowicz; Rajni Sinha; Rajinder S Grover; Leon Bernal-Mizrachi; Jeanne Kowalski; Will Donnellan; Angelina The; Vishnu Reddy; David L Jaye; James Foran
Journal:  Leuk Lymphoma       Date:  2013-02

5.  Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy.

Authors:  Liang Wang; Panpan Liu; Xiaoqin Chen; Qirong Geng; Yue Lu
Journal:  Med Oncol       Date:  2011-08-30       Impact factor: 3.064

Review 6.  Primary sacral non-germinal center type diffuse large B-cell lymphoma with MYC translocation: a case report and a review of the literature.

Authors:  Asami Shimada; Kei-Ji Sugimoto; Mutsumi Wakabayashi; Hidenori Imai; Yasunobu Sekiguchi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ota; Norio Komatsu; Masaaki Noguchi
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

7.  Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future.

Authors:  Rajni Sinha; Loretta Nastoupil; Christopher R Flowers
Journal:  Blood Lymphat Cancer       Date:  2012-04-19

Review 8.  Next-generation prognostic assessment for diffuse large B-cell lymphoma.

Authors:  Ashley D Staton; Jean L Koff; Qiushi Chen; Turgay Ayer; Christopher R Flowers
Journal:  Future Oncol       Date:  2015-08-20       Impact factor: 3.404

9.  Clinico-Pathologic Profile and Treatment Outcomes of Patients with Diffuse Large B Cell Lymphoma Based on Cell of Origin Classification.

Authors:  Sohan Singh Mandloi; Divya Bala Thumaty; Yadav Nisha; Smita Kayal; Prasanth Ganesan; Sajini Elizabeth Jacob; Debdatta Basu; Biswajit Dubashi
Journal:  Indian J Hematol Blood Transfus       Date:  2020-07-27       Impact factor: 0.900

10.  Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients.

Authors:  Noel F C C de Miranda; Konstantinos Georgiou; Longyun Chen; Chenglin Wu; Zhibo Gao; Apostolos Zaravinos; Susana Lisboa; Gunilla Enblad; Manuel R Teixeira; Yixin Zeng; Roujun Peng; Qiang Pan-Hammarström
Journal:  Blood       Date:  2014-08-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.